CO5271676A1 - Metodo para administrar un inhibidor de fosfodiesterasa 4 - Google Patents
Metodo para administrar un inhibidor de fosfodiesterasa 4Info
- Publication number
- CO5271676A1 CO5271676A1 CO00081570A CO00081570A CO5271676A1 CO 5271676 A1 CO5271676 A1 CO 5271676A1 CO 00081570 A CO00081570 A CO 00081570A CO 00081570 A CO00081570 A CO 00081570A CO 5271676 A1 CO5271676 A1 CO 5271676A1
- Authority
- CO
- Colombia
- Prior art keywords
- composition
- formulation
- drug
- compared
- side effects
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Un método para aumentar la dosis o la exposición sistémica de una composición inhibidora de la PDE4, comparada con una dosis doble en un momento único, y reducir la gravedad o eliminar la presencia de efectos secundarios, método que comprende: formular una preparación de liberación controlada de dicha composición con un excipiente farmacéuticamente aceptable que pueda formar una composición de liberación controlada que retrase la aparición en el plasma de cantidades detectables de dicha composición cuya velocidad de aumento de concentración plasmática es de un 10% menor si se compara con una formulación de liberación inmediata que contenga igual cantidad de composición y por la misma vía de administración. Un método para reducir o eliminar la aparición de efectos secundarios de una composición inhibidora de la PDE4 que incluye administrar dicha composición en una formulación que produzca una reducción de velocidad en el aumento de su concentración plasmática en un 10% menor si se compara con una formulación de liberación inmediata que contenga igual cantidad de composición y por la misma vía de administración. Un método para reducir la gravedad o eliminar o evitar la aparición de uno o más efectos secundarios de un compuesto que inhibe la PDE4, y dicho método comprende administrar el fármaco en una formulación y/o de una manera que da como resultado un retraso en la aparición en el plasma de cantidades detectables de dicho fármaco, y da como resultado una reducción de la velocidad de aumento en la concentración plasmática de dicho fármaco de al menos aproximadamente 10%, cuando se compara con la de una formulación de liberación inmediata que contiene la misma cantidad de fármaco administrada por la misma vía. <EMI FILE="00081570_1" ID="1" IMF=JPEG >
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16247799P | 1999-10-29 | 1999-10-29 | |
US16264199P | 1999-11-01 | 1999-11-01 | |
US17981700P | 2000-02-02 | 2000-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5271676A1 true CO5271676A1 (es) | 2003-04-30 |
Family
ID=27388757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00081570A CO5271676A1 (es) | 1999-10-29 | 2000-10-26 | Metodo para administrar un inhibidor de fosfodiesterasa 4 |
Country Status (29)
Country | Link |
---|---|
US (1) | US20030212112A1 (es) |
EP (1) | EP1225884A4 (es) |
JP (1) | JP2003513038A (es) |
KR (1) | KR20020050249A (es) |
CN (1) | CN1387433A (es) |
AP (1) | AP2002002446A0 (es) |
AR (1) | AR026254A1 (es) |
AU (1) | AU772909B2 (es) |
BG (1) | BG106623A (es) |
BR (1) | BR0015039A (es) |
CA (1) | CA2389293A1 (es) |
CO (1) | CO5271676A1 (es) |
CZ (1) | CZ20021443A3 (es) |
DZ (1) | DZ3249A1 (es) |
EA (1) | EA200200502A1 (es) |
HK (1) | HK1049105A1 (es) |
HU (1) | HUP0203682A3 (es) |
IL (1) | IL148813A0 (es) |
MA (1) | MA25562A1 (es) |
MX (1) | MXPA02004220A (es) |
NO (1) | NO20021937L (es) |
NZ (1) | NZ518002A (es) |
OA (1) | OA12078A (es) |
PE (1) | PE20011004A1 (es) |
PL (1) | PL355262A1 (es) |
SK (1) | SK7292002A3 (es) |
TR (1) | TR200201150T2 (es) |
UY (1) | UY26422A1 (es) |
WO (1) | WO2001032165A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR029984A1 (es) * | 2000-07-27 | 2003-07-23 | Smithkline Beecham Corp | Metodo para reducir las exacerbaciones asociadas copd ambito |
MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
DE10207160A1 (de) * | 2002-02-20 | 2003-12-18 | Altana Pharma Ag | Darreichungsform enthaltend PDE 4-Hemmer als Wirkstoff |
UA88523C2 (ru) * | 2002-05-28 | 2009-10-26 | Алтана Фарма Аг | Фармацевтический препарат рофлумиласта для местного применения |
US6822114B1 (en) | 2002-10-08 | 2004-11-23 | Albemarle Corporation | Process for production of fluoroalkoxy-substituted benzamides and their intermediates |
DK1606261T3 (da) | 2003-03-10 | 2010-01-18 | Nycomed Gmbh | Hidtil ukendt fremgangsmåde til fremstilling af roflumilast |
CA2520779A1 (en) * | 2003-03-31 | 2004-11-11 | Kyowa Hakko Kogyo Co., Ltd. | Agent for intra-airway administration |
US20050026883A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
DK1861074T3 (da) | 2005-03-16 | 2013-07-29 | Takeda Gmbh | Smagsmaskeret doseringsform indeholdende roflumilast |
WO2011068721A1 (en) * | 2009-12-03 | 2011-06-09 | Opko Health, Inc. | Hypersulfated disaccharide formulations |
CN103536582A (zh) * | 2013-10-12 | 2014-01-29 | 云南龙海天然植物药业有限公司 | 罗氟司特干粉吸入剂 |
US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
EP3870261B1 (en) | 2019-12-13 | 2024-01-31 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4684516A (en) * | 1983-08-01 | 1987-08-04 | Alra Laboratories, Inc. | Sustained release tablets and method of making same |
AR028986A1 (es) * | 1999-02-23 | 2003-06-04 | Smithkline Beecham Corp | USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA |
AR035987A1 (es) * | 1999-03-01 | 2004-08-04 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio |
-
2000
- 2000-10-26 AP APAP/P/2002/002446A patent/AP2002002446A0/en unknown
- 2000-10-26 EP EP00975385A patent/EP1225884A4/en not_active Withdrawn
- 2000-10-26 CA CA002389293A patent/CA2389293A1/en not_active Abandoned
- 2000-10-26 AU AU13445/01A patent/AU772909B2/en not_active Ceased
- 2000-10-26 BR BR0015039-8A patent/BR0015039A/pt not_active IP Right Cessation
- 2000-10-26 OA OA1200200126A patent/OA12078A/en unknown
- 2000-10-26 DZ DZ003249A patent/DZ3249A1/fr active
- 2000-10-26 PL PL00355262A patent/PL355262A1/xx unknown
- 2000-10-26 CZ CZ20021443A patent/CZ20021443A3/cs unknown
- 2000-10-26 CN CN00815150A patent/CN1387433A/zh active Pending
- 2000-10-26 KR KR1020027005448A patent/KR20020050249A/ko not_active Application Discontinuation
- 2000-10-26 AR ARP000105644A patent/AR026254A1/es not_active Application Discontinuation
- 2000-10-26 SK SK729-2002A patent/SK7292002A3/sk unknown
- 2000-10-26 WO PCT/US2000/029453 patent/WO2001032165A1/en not_active Application Discontinuation
- 2000-10-26 EA EA200200502A patent/EA200200502A1/ru unknown
- 2000-10-26 MX MXPA02004220A patent/MXPA02004220A/es unknown
- 2000-10-26 JP JP2001534370A patent/JP2003513038A/ja not_active Withdrawn
- 2000-10-26 NZ NZ518002A patent/NZ518002A/en unknown
- 2000-10-26 HU HU0203682A patent/HUP0203682A3/hu unknown
- 2000-10-26 IL IL14881300A patent/IL148813A0/xx unknown
- 2000-10-26 CO CO00081570A patent/CO5271676A1/es not_active Application Discontinuation
- 2000-10-26 TR TR2002/01150T patent/TR200201150T2/xx unknown
- 2000-10-27 PE PE2000001157A patent/PE20011004A1/es not_active Application Discontinuation
- 2000-10-30 UY UY26422A patent/UY26422A1/es not_active Application Discontinuation
-
2002
- 2002-04-17 BG BG106623A patent/BG106623A/bg unknown
- 2002-04-24 NO NO20021937A patent/NO20021937L/no not_active Application Discontinuation
- 2002-04-26 MA MA26618A patent/MA25562A1/fr unknown
- 2002-12-19 HK HK02109231.8A patent/HK1049105A1/zh unknown
-
2003
- 2003-05-02 US US10/429,666 patent/US20030212112A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PE20011004A1 (es) | 2001-09-28 |
WO2001032165A1 (en) | 2001-05-10 |
HUP0203682A2 (hu) | 2003-04-28 |
DZ3249A1 (fr) | 2001-05-10 |
EA200200502A1 (ru) | 2002-10-31 |
EP1225884A4 (en) | 2005-06-15 |
US20030212112A1 (en) | 2003-11-13 |
AU772909B2 (en) | 2004-05-13 |
AP2002002446A0 (en) | 2002-03-31 |
PL355262A1 (en) | 2004-04-05 |
NZ518002A (en) | 2004-01-30 |
AU1344501A (en) | 2001-05-14 |
OA12078A (en) | 2003-05-28 |
BG106623A (bg) | 2003-02-28 |
CN1387433A (zh) | 2002-12-25 |
NO20021937L (no) | 2002-05-30 |
HUP0203682A3 (en) | 2003-10-28 |
HK1049105A1 (zh) | 2003-05-02 |
MA25562A1 (fr) | 2002-10-01 |
JP2003513038A (ja) | 2003-04-08 |
KR20020050249A (ko) | 2002-06-26 |
NO20021937D0 (no) | 2002-04-24 |
BR0015039A (pt) | 2002-06-25 |
AR026254A1 (es) | 2003-02-05 |
SK7292002A3 (en) | 2002-12-03 |
EP1225884A1 (en) | 2002-07-31 |
UY26422A1 (es) | 2001-07-31 |
IL148813A0 (en) | 2002-09-12 |
TR200201150T2 (tr) | 2002-09-23 |
MXPA02004220A (es) | 2002-10-17 |
CA2389293A1 (en) | 2001-05-10 |
CZ20021443A3 (cs) | 2003-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5271676A1 (es) | Metodo para administrar un inhibidor de fosfodiesterasa 4 | |
UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
YU13695A (sh) | Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije | |
RS52149B (sr) | Farmaceutska kombinacija mikronizovanog drospirenona i estrogena za terapiju zamene hormona | |
CR6458A (es) | Composiciones de valdecoxib | |
AU2002360462A1 (en) | Compositions containing both sedative and non-sedative antihistamines | |
FR2714378B1 (fr) | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. | |
SE9704870D0 (sv) | New pharmaceutical formulation I | |
WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
AR033444A1 (es) | Forma solida de dosificacion util para la administracion oral de un compuesto activo de nicotina, a traves de la mucosa y uso de un compuesto activo de nicotina para prepararla | |
AP1776A (en) | Reconstitutable parenteral composition containing a cox-2 inhibitor. | |
WO2002096428A1 (en) | Pharmaceutical combinations | |
AU2002305952A1 (en) | Pharmaceutical combinations | |
CO5200778A1 (es) | Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis | |
AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
CO5190664A1 (es) | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 | |
BR0308229A (pt) | Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio | |
NO996049L (no) | Farmasoeytisk preparat med kontrollert frigjoering, med ACE- inhibitor som aktiv ingrediens | |
CO5150233A1 (es) | Formulacion de liberacion controlada para administrar un inhibidor de pde4 | |
KR920019350A (ko) | 자기면역질환요법을 위한 약제조성물 | |
McKinlay et al. | Use of WIN 51711 to prevent echovirus type 9-induced paralysis in suckling mice | |
EP1150665A2 (en) | Use of statins for treating viral infections | |
ES2105923B1 (es) | Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv). | |
AR026631A1 (es) | ''3-4-dihidroquinazolinas 5,6-disustituidas'' | |
HRP20090256T1 (en) | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |